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Summary
BACKGROUND
 Human Papillomavirus (HPV) has been associated with a subset of Head and Neck 
Squamous Cell Carcinoma (HNSCC) in particular Oropharyngeal Carcinoma.
OBJECTIVE 
 To determine the prevalence and Clinicopathological predictors of high-risk HPV among 
patients with HNSCC at Kenyatta National Hospital (KNH) Nairobi, Kenya.
MATERIALS 
 One hundred and sixty(160) patients who presented themselves to the ENT clinic between 
2015 and 2017 with HNSCC had their history taken. A complete physical examination was done 
along with the appropriate haematological and radiological work-up. Two tissue biopsies were 
taken from the primary tumour for histology and real time polymerase chain reaction. 
METHODOLOGY
 One hundred and sixty(160) patients with HNSCC aged 16 to 87 years were recruited 
and set in groups of six. These groups were based on the primary site of the tumour present such 
as; Oral cavity, Oropharynx, Nasopharynx, Hypopharynx, Larynx and Sinonasal. There were 117 
(73.1%) males and 43 (26.9%) female participants. Twelve 12(7.5%) patients tested positive for 
high risk HPV. The HPV genotypes detected were 56, 52 and 33. There were no predictors for 
HPV positivity. 
CONCLUSION 
 High risk HPV prevalence was low among HNSCC patients at Kenyatta National Hospital.
No HPV 16 nor 18. The positive patients did not have profiles that matched those of HPV-positive 
HNSCC globally.
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Introduction
 Cancer is a growing public health concern 
worldwide and more so in Africa. In Kenya, cancer is 
the third most common cause of death after infectious 
and cardiovascular diseases contributing 7% of the total 
mortality annually. 
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 According to the Nairobi Cancer Registry, 
HNSCC was the second most common malignancy 
reported after cancer of the breast during the period 
2000 to 2002 [1]. 
 
 A rapid rise of cancer is projected in many 
developing countries due to increased exposure to 
risk factors including tobacco, alcohol, environmental 
Carcinogens, HIV, and  Human Papillomavirus [2]. 
 The overall global incidence of HNSCC has 
increased by about 30% since 1988. This has been 
attributed to an increase in HPV - related cancers, 
in particular, Oropharyngeal Squamous Carcinoma 
(OPSCC) [3]. 
 The incidence of cancers attributable to HPV 
in Kenya, showed that, cancer of the cervix uteri, other 
anogenital cancers, Head and Neck cancers stand at 40 
in every 100,000 women, 1.9 in every 100,000 male  and 
0.2 in 100,000 people respectively [4]. 
 This is despite the fact that all three groups of 
cancer are caused by the same high risk HPV subtypes. 
 Worldwide, HPV related cervical cancer occurs 
predominantly in less developed countries. While North 
America and Northern Europe have the bulk of HPV 
attributable to Head and Neck cancers. [5]. 
 
 Many and more countries are setting up HPV 
vaccination programs for both girls and boys as a 
measure of prevention on HPV attributable cancers. 
 Such programs can only be effective if the target 
population is well defined based on reliable statistics.
Sudy Site
 The study was done at Kenyatta National 
Hospital the largest and oldest hospital in kenya. 
KNH is a public tertiary, referral hospital in East and 
Central Africa, specifically, The Republic of Kenya. It 
also serves as a hands on facility for the University of 
Nairobi.
 Kenyatta National Hospital is situated in the 
capital City of kenya (Nairobi), just a few kilometers 
from the Central business.
 It has a bed capacity of 2000 beds and catters for 
approximately 3000 out patients per day. Some of whom 
had,  Ear Nose and Throat – Head and Neck (ENT-HN) 
related ailments. We recruited our participants from the 
KNH wards, ENT-HN and Maxillofacial Clinics. 
 Kenyatta National Hospital receives hundreds 
of patients 24hrs including those from the neighbouring
countries like Uganda, Tanzania, Sudan, Somalia 
Ethiopia Eritrea, Rwanda, Burundi, DRC Republic etc.
Materials
 One hundred and sixty(160) patients who 
presented themselves to the ENT Clinic between 2015 
and 2017 with suspected Head and Neck Squamous Cell 
Carcinoma (HNSCC) at Kenyatta National Hospital 
from the wards, ENT-HN and Maxillofacial clinics 
were recruited.
 There were 117 (73.1%) male and 43 (26.9%) 
female. Twelve (7.5%) patients tested positive for high 
risk HPV. The HPV genotypes detected were 56, 52 and 
33.
 Their demographic data and detailed history 
with a focus on risk factors for HNSCC as well as 
purported risk factors for HPV - positive HNSCC 
were taken and recorded. 
 
 Information concerning their characteristics 
and symptoms was as below;
 (a). Smoking, alcohol and other substance  
  use
 (b). Exposure to irritants or radiation
 (c) History in keeping with 
  gastro-oesophageal or    
  Laryngopharyngeal reflux
 (d) Sexual Orientation and Practices was  
  also sought. 
 
Methodology
 A total of the one hundred and sixty patients 
with HNSCC, confirmed by histology, aged between 
16 and 87 years were enrolled in the study and set in 
groups of six . 
 
 The mean and median age was 51.6 and 54 
years respectively. There were 117 (73.1%) male and 43 
(26.9%) female. 
 The patients' groups of six, were based on the 
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primary site of the tumour present as indicated below; 






 A complete Ear Nose and Throat – Head and 
Neck (ENT-HN) examination was done. Standard 
haematological tests for all HNSCC patients, comprised 
of full;
 a. Haemogram, 
 b. Renal
 c. Liver function tests 
 d. ELISA for HIV were requested.
 Appropriate radiological work-up for the tumour 
in question including but not limited to CT-Scan and 
chest x-ray were carried out. 
 TNM staging as per AJCC 2010 for specific 
sites was done and group staging made. 
 Tumour biopsy specimens were taken as per 
the unit protocol for histopathological diagnosis. From 
each subject, two tissue biopsies were taken and one was 
fixed in 10% buffered formal saline for histopathological 
analysis.
 The other sample was placed in a specimen bottle 
and frozen at -80°C. At least two hundred specimens 
were collected and frozen from which one hundred and 
sixty histologically confirmed HNSCC specimens were 
selected for DNA extraction. 
 
DNA Extraction
 Approximately 25 mg of each frozen tissue 
was cut into small pieces and placed in a 1.5 ml micro-
centrifuge tube. 100 μl of Buffer ATL was added to each 
sample followed by 20 μl of proteinase K. 
 The contents were mixed by vortexing and 
incubated at 56°C in a shaking water bath until the 
tissues were completely lysed (overnight). The samples 
were then briefly centrifuged. 
 200 μl of Buffer AL was added to each sample 
and mixed by pulse-vortexing for 15 seconds then 
incubated at 70°C for 10 minutes. The mixture was 
briefly centrifuged to remove drops from inside the lid. 
 200 μl of 100% ethanol was added to the 
sample and mixed by pulse-vortexing for 15 seconds 
then centrifuged to remove drops from inside the lid. 
 The mixture was pipetted into the QIAamp 
Mini spin column in a 2 ml collection tube, which was 
closed and centrifuged at 8000 revolutions per minute 
(rpm) for 1 minute. 
 The QIAamp Mini spin column was placed in 
a clean 2 ml collection tube and the tube containing the 
filtrate discarded. 
 The QIAamp Mini spin column was opened 
carefully and 500 μl of Buffer AW1 added then closed 
again. The mixture was centrifuged at 8000 rpm for 1 
minute. The tube containing the filtrate was discarded. 
 500 μl of Buffer AW2 was added to the 
QIAamp Mini spin column and the mixture centrifuged 
at 14,000 rpm for 3 minutes. 
 The QIAamp Mini spin column was placed in 
a new 2 ml collection tube and centrifuged at full speed 
for 1 minute to eliminate the Buffer AW2 carryover. 
 The QIAamp Mini spin column was put in a 
clean 1.5 ml centrifuge tube and the collection tube 
discarded. 
 200 μl of Buffer AE was added and incubated 
at room temperature for 1 minute before centrifuging at 
8000 rpm for 1 minute. 
 This last step was repeated for increased DNA 
yields. The resultant eluate containing HPV DNA was 
stored at -20°C for HPV DNA genotyping.
HPV DNA Genotyping
 Real Time PCR was performed on 10 microliters 
of the extracted DNA using HPV Genotype Real-TM 
Quant kit from SACACE as per the manufacturer’s 
instructions. 
 The kit detects 14 genotypes (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66, 68) of high risk Human 
Papillomavirus. 
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 For the sample to be tested as per the 
manufacturer’s instructions, Reaction mix was made 
using;
 1. Hot Start DNA Polymerase, 
 2. PCR - buffer - FRT 
 3. PCR mix-1 
 Four test tubes for each clinical sample, four 
tubes for K2 standards and four tubes for negative 
control were set up. 
 Ten microlitres of extracted DNA sample was 
added to each test tube. For each panel, 10 μl of controls 
and standards were prepared for cycling.
 The test tubes were closed and transferred 
into the Real Time Thermal cycler (Rotor Gene Q, 
QIAGEN). The machine was programmed as per the 
kit’s PCR cycling conditions. 
 PCR was performed and the results interpreted 
using the Rotor Gene Q software. A signal was 
considered to be positive if the corresponding 
fluorescence accumulation curves crossed the threshold 
line. 
Data Inquiry
 Data analysis was performed using SPSS 
version 21.0 statistical software. Descriptive analysis 
was performed on all variables and summarized into 
frequency tables and charts. 
 Odds ratios was done to test for the strength 
of association between Independent and Dependent 
variables. 
 Pearson Chi square was applied to categorical 
data to test for association between Independent and 
Dependent variables. Fishers exact test was employed 
when cell numbers were small.
RESULTS
 A total of one hundred and sixty patients with 
HNSCC, confirmed by histology, aged 16 to 87 years 
were enrolled in the study. The mean and median age 
was 51.6 and 54 years respectively. There were 117 
(73.1%) males and 43 (26.9%) females. 
 The patients were grouped into six, based on 
the primary site of the tumour as; 
 a. Oral cavity, 
 b. Oropharynx, 
 c. Nasopharynx, 
 d. Hypopharynx, 
 e. Larynx
 f. Sinonasal.
 Majority of the patients had Carcinoma of the 
Nasopharynx  (38.8%), followed by Larynx (29.4%), 
Sinonasal (11.3%), Oral Cavity (8.8%), Hypopharynx 
(6.9%) and Oropharynx  (5.0%). 
 The male to female ratio for all the study 
subjects collectively was approximately 3:1. 
 All tumour groups had more male than female 
except for Oral Cavity Carcinoma, where the ratio was 
1:1.  Carcinoma of the larynx had the largest male to 
female ratio of about 23:1.
 Patients presented with different combinations 
of symptoms dictated by the primary site of the tumour. 
At least 30% of the patients presented with nasal 
obstruction, hoarseness, neck swelling and difficulties 
in breathing.
 The exposure of patients to risk factors for 
HNSCC either in the past or current is summarized in 
Table 1.
Some patients were exposed to more than one risk 
factor. Cigarette smoking and drinking beers were the 
most frequent risk factors. Few patients had used khat 
and marijuana. 
 The four patients who had previous irradiation 
to the neck were presenting with either residual or 
recurrent disease treated with radiotherapy within five 
years of the first course.  
 GERD and/or LPR symptoms were present in 
6.9% of patients. Three patients reported exposure to 
irritants with one having recurrent throat irritation. 
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Table I: Exposure to Risk Factors 
Risk factor Frequency Percentage (%)
Cigarette smoking 79 49.4
Tobacco chewing 3 1.9
Khat chewing 10 6.3
Marijuana use 3 1.9
Alcohol 
• Beer 60 37.3
• Spirits 17 10.7
• Wine 7 4.4
• Chang’aa (unpurified spirit) 15 9.4
• Unprocessed                                                                                                                                         
  brews
37 23.1
Previous head and neck radiation 4 2.5
Exposure to irritants 3 1.8
GERD/LPR 11 6.9
Others 1 0.6
 Only nine of the study subjects were not sexually 
active. These were mainly young patients aged nineteen 
(19)years and less.
 None of the patients was homosexual or 
bisexual. There was, however, one patient who admitted 
to having engaged in anogenital sex. Of the 151 sexually 
active patients, 19 could not recall their age at sexual 
debut. 
 Two (1.3%) of the patients had early sexual 
debut defined as sexual debut at less than 15 years age 
[6].
  Patients who had at least four lifetime sexual 
partners were classified as having had multiple sexual 
partners [7].
 Based on this definition, 45(29.8%) of the 
sexually active patients had multiple sexual partners. 
Of the remaining 106 (70.2%) sexually active patients, 
15(9.9%)could not remember how many lifetime sexual 
partners they had had.
 The disease stage was determined on the basis 
of clinical and radiological examination. There were no 
distant metastases detected. 
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Only 10 (6.3%) of the patients tested positive for HIV. 
These consisted of 4 female and 6 males aged 23 to 57. 
 All the six male had a history of smoking and 
used alcohol. The HIV positive patients who tested 
positive to the following ailments  were as follows; 
 (a.) 6  had Nasopharyngeal 
 (b.) 2  had Oropharyngeal
 (c.) 1  had Hypopharyngeal  
 (d.) 1  had Laryngeal Carcinoma. 
 Two 2 (20%) of the HIV positive patients tested 
positive for HPV. Both had Nasopharyngeal Carcinoma 
and HPV subtype 56. 
Figure I: Histological Grading of Tumours
 The Primary tumour (T), regional nodal staging 
(N) and distant metastases (M) as per the AJCC 2010 
staging was done and a group staging for HNC done 
thereafter. 
 Only 12.6% of the patients had early tumours 
(stage I and II). Four (2.5%) patients had recurrent 
tumours. Cystic lymph nodes were only found in five 
patients.  
 Three of these patients with cystic lymph nodes 
had Nasopharyngeal Narcinoma, one Sinonasal and one 
Oral Cavity Carcinoma.
 All tumours were assigned the WHO 
histological grading I to IV. 
The results are presented in figure 1 below.
 Majority tumours of the oral cavity, oropharynx, 
hypopharynx and larynx were of better differentiation 
than the nasopharyngeal and sinonasal tumours, which 
were mainly poorly differentiated or undifferentiated. 
The NPC specimens were separately assigned WHO 
type I NPC (6.4%), type II (17.7%) and type III (75.8%).
 Twelve 12(7.5%) of the study patients tested 
positive for HPV by real time Polymerase Chain 
Reaction. 
 The only high-risk HPV genotypes detected 
were 56 (10 patients) 33 and 52 (one patient each). No 
single patient tested positive for two or more genotypes. 
 The primary tumour types and profiles of 
patients that tested positive for HPV are shown in (Table 
2) next page. There was no characteristic that was 
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African Journal of Health Sciences, Volume 32, Issue No. 2, March - April 2019 7
Table II: HPV Association with Patient and Tumour Factors




POSITIVE NEGATIVE LOWER UPPER
Age:          ≤ 60 years
                  > 60 years
6           (8.5%) 65 (91.5%) 0.7 1.27 0.393 4.144
6           (6.7%) 83 (93.3%)
Gender:    Male
                  Female
6           (5.1%) 111(94.9%) 0.87 0.3 0.101 1.097
6           (14.0%) 37 (86.0%)
Tobacco Smoking:        Yes
                                         No.
2           (2.4%) 80 (97.6%) 0.016 0.170 0.36 0.806
10         (12.8%) 68 (86.9%)
Tobacco chewing:          Yes
                                         No.
1           (16.7%) 5 (83.3 %) 0.3 2.6 0.279 24.250
11         (7.1%) 143 (92.9%)
Miraa chewing:            Yes
                                         No.
2           (20.0%) 8 (80.3%) 0.1 3.5 0.654 18.724
10         (6.7%) 140 (93.3%)
Marijuana use:            Yes 0           (0%) 3 (100%) 1.0 1.083 1.035 1.133
                                        No, 12         (7.6%) 145 (92.4%)
Alcohol Drinker
Non-drinker 
4           (5%) 80 (95%) 0.231 0.425 0.123 1.473
8           (10.5%) 68(89.5%)
Previous head & neck   Yes
 irradiation :                   No
1           (25.0%) 3 (75.0%) 0.2 4.39 0.421 45.830
11         (7.1%) 145 (92.9%)
Exposure to irritants:  Yes
                                        No.
0           (0%) 3 (100%) 1.0 1.0 1.035 1.133
12         (7.6%) 145 (92.4%)
GERD/LPR:                     Yes
                                        No
1           (9.1%) 10 (90.9%) 0.5 1.255 0.147 10.720
11         (7.4%) 138 (92.6%)
Age of sexual debut: None/Early
                                     Late
2           (18.2%) 9 (81.8%) 0.206 2.98 0.560 15.953
9           (6.9%) 121 (93.1%)
No. of sexual partners:   Multiple   3           (6.7%) 42(93.3%) 1.0 0.9 0.234 3.851
7           (7.0%) 93 (93.0%)
Site of tumour: Oral cavity
                       Oropharynx
                         Nasopharynx
                         ypopharynx
                         Sinonasal
2           (14.3%) 12 (85.7%) 0.3 0.9 0.567 1.448
0           (0%) 8 (100%)
7           (11.3%) 55 (88.7%)
0           (0%) 11 (100%)
2           (11.1% 16 (88.9%)
Histological grade:     I
                                      II
                                      III
                                      IV
2           (5.7%) 43 (95.6%) 0.6 1.5 0.890 2.684
2           (16.7%) 33 (94.3%)
1           (6.7%) 14 (93.3%)
7           (10.8%) 58 (89.2%)
HIV Status: Positive
                    Negative
2           (20.0%) 8 (80.0%) 0.1 3.50 0.654 18.724
10         (6.7%) 140 (93.3%)
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DISCUSSION
 HPV related Head and Neck cancers are 
associated with particular characteristics usually not 
present in HPV negative cancers. 
 These Clinicopathological profiles that are 
characteristic of HPV positive tumours include;
 1. Male gender 
 2. Younger age
 3. Higher socioeconomic status 
 4. Marijuana use 
 5. Minimal tobacco and/or alcohol  
  consumption   
 6. Orogenital sex
 7. Multiple sex partners
 8. HIV co-infection 
 9. Early T stage 
 10. Advanced Nodal Stage with nodes  
  being cystic. 
 The histology tends to be consistently poorly 
differentiated and non-keratinizing with basaloid 
features in contrast to the HPV- negative HNSCC that 
are moderately differentiated and keratinizing [8-9]
 The profile of the HPV positive patients in this 
study is presented in Table II (Pg 7) behind.  None 
of this patients had the typical characteristics of HPV 
patients as described in  some literature. 
 Twelve 12(7.5%) of the study patients tested 
positive for HPV by Realtime polymerase chain reaction. 
 This is consistent with studies from the African 
continent, which have recorded a low prevalence of 
HPV in HNSCC [10-17].  
 A study done at KNH to determine P16 
expression by IHC in 103 formalin - fixed paraffin 
embedded (FFPE) HNC blocks between 2008 and 2013 
came up with an overall prevalence of 14.6%. 
 The majority were reported in specimens from 
the following as below;  
 The oral cavity   (46.67%),
 The larynx    (26.67%) 
 The pharynx   (26.67%) [18].  
 The relatively high prevalence rates in these 
FFPE tissues can be attributed to the HPV detection 
method employed which has a high sensitivity (100%) 
but low specificity (79%) [19]. 
 In Nigeria, HPV determination in 149 HNC 
FFPE specimens was attempted but PCR amplification 
and Linear Array genotyping was successful in only 49 
and 17 specimens respectively. No HPV was detected in 
any of the specimens [14]. 
 A multicentre cross-sectional study from 
Senegal assessing the prevalence of HPV in 117 Head 
and Neck Cancer specimens found only 4 cases (3.4%) 
with HPV DNA type 16, 35 and 45. None of the HPV 
positive patients showed P16INK4a over expression 
[15]. 
 It is important to note that majority of the study 
subjects who had laryngeal were (64), oral cavity (41), 
with oropharyngeal and pharyngeal being only 5 and 7 
respectively. 
 In Mozambique no HPV was found among the 
patients with HNC [16]. 
 In Malawi a prevalence of HPV in HNC by p16 
IHC of 17% was reported. Majority of these were either 
oral cavity or oropharyngeal cancer specimens [17]. 
 The relatively high figure may, be attributed to 
the test modality. 
 Cameroon recorded low (5%) presence of HPV 
in oral swabs and rinses from HIV patients but higher 
(28.6%) HPV from OPSCC by p16 IHC and ISH [20]. 
 Central African Republic yielded only 0.74% 
HPV by PCR on 25 HNC FFPE specimens [21]. 
 Three different studies from Ghana have shown 
consistent findings for HPV in HNSCC (19.23% and 
18%) with predominantly HPV 16 subtype but low 
positivity in OSCC (3.4%) [22, 23, 24]. 
 Sudan has, in the latter years, reported unique 
results among African countries. Alternatively with 
some reports supporting HPV as a significant factor 
in oral cancer causation alongside toombak (tobacco 
species) use [25]. 
 A study of 150 HNSCC patients showed an 
overall positivity of 4% predominantly HPV 16 and 
with more presence in oral cavity and pharynx [26]. 
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 In yet another Sudanese study, HPV was found 
by PCR sequencing in 39 (27%) of 145 FFPE oral cavity 
samples from toombak users. Non-users of toombak 
had 7% HPV positivity. Oral brushings from toombak 
users without oral cancer or dysplasia tested positive 
for HPV in 40%. of them. The authors concluded that 
HPV infections are common and may influence cancer 
development [27].
 It is important to note that toombak has high 
levels of nicotine is an independent risk factor for HNC. 
 In another case, a control design study 
consisting of 40 oral SCC patients and 15 benign oral 
lesions in Sudan, HPV (four type 18 and two type 16) 
presence by PCR was 15% among cases, none within 
controls leading to the conclusion that, HPV 18 and 16 
may have a causal role in oral SCC in Sudan [25-28].
 In Morocco, HPV DNA was detected in 34% 
of 70 patients with Nasopharyngeal Carcinoma with 
20.8% of them having HPV 31 and the rest HPV 59, 16, 
18, 33, 35 and 45 [29]. 
 Unlike the above two northern African countries 
who share an Arabian decent with Egypt, the latter has 
reported low (3.6%) HPV positivity in laryngeal cancer 
but high prevalence in both OPSCC (28%) and OSCC 
(37%) [30, 31]. 
 Whether this variance is only influenced by the 
specific sites of study is not clear. What seems to emerge 
is that in North Africa and the greater Middle East there 
are varying HPV prevalence rates. The wide range is 
attributed to limited numbers and scope of studies [32]. 
 Studies on HPV in cancer of the cervix have 
shown similarities between the North African countries 
and Europe attributing the similarities to geographical 
proximity [33]. 
 A review of 60 published studies from 1995 to 
2005 on the worldwide status of HPV in 5046 HNSCC 
specimens using PCR - based methods found an overall 
HPV prevalence of 25.9% with the individual sites 
having a prevalence of 35.6% for the Oropharynx, 24% 
for the Larynx and Pharynx and 23.5% for the Oral 
Cavity [34]. 
 From the foregoing discussion, it is clear that 
HPV - related HNSCC has glaring disparities in its 
distribution. 
The Low Prevalence Of HPV in African 
Countries
 This might have been influenced by an 
interaction of several factors that have not been verified 
but can be extrapolated from other disease processes. 
 Among them are socio-cultural, genetic and 
environmental factors. Risky sexual behavior has been 
linked to oral HPV acquisition. This includes early 
sexual debut, multiple sexual partners and prior sexual 
practice of the partner. 
Marital Status
 Rather than the number of sexual partners. 
Marital status has been shown to be more predictive of 
oral HPV infection with higher rates occurring among 
divorced, separated and widowed individuals than the 
married or cohabiting persons [35]. 
Sexual Practices and Orientation 
 Generally divergent across the globe sexual 
practices and orientation raises concern in oral HPV 
infection. In America, 78% of men were reported to 
have engaged in oral sex compared to only 9% of Indian 
origin [36]. 
 No statistics on these practices are available in 
Kenya and most of Africa but observations are that, they 
are less compared to the developed world. This may 
contribute to the low prevalence of HPV in HNSCC in 
Africa.
 Racial disparity with regard to HPV positive 
HNSCC has been reported in America with lower 
prevalence among African Americans compared to 
white Americans. 
 Among the reasons fronted for the disparities 
are differences in sexual behavior, marijuana use, 
genetic differences between races, differences in host 
response to HPV infection and intratypic variation of 
HPV 16 within geographical areas [37].
 A multi-institutional retrospective cohort study 
among black and white HNSCC patients showed HPV-
inactive disease to be common among both black and 
white patients (31% and 38%) but HPV-active disease 
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to be less prevalent in black compared to white patients 
(0% versus 29%) [38]. 
 In another study from America equal numbers 
of black and white adolescent males were sexually 
active but with whites 2.7 times more likely to have 
engaged in oral sex with a female and 1.4 times likely 
to have received oral sex from a female while the blacks 
were only 1.4 times likely to have engaged in genital-to-
genital sex with a female. At the same time, adolescent 
white females were twice as likely as black females to 
have engaged in oro-genital sex [39]. 
 These observations further confirm that other 
than environment, race is crucial in as far as sexual 
orientation and by extension HPV-related HNC is 
concerned. The trend is likely to be reproduced among 
whites and blacks on other continents including Africa. 
 It is noteworthy in this Kenyan study that all the 
patients were black and there was only one subject out 




 Types, Subtypes and Variants are based on the 
L gene sequence similarities [40]. 
 There are several phylogenetic variants of HPV 
16 isolated in cervical cancer patients like the European, 
North-American-1, Asian, European-Asian, Asian-
American, African-1, African-2, etc. [41]. 
 Different biological properties of HPV 16 
variants have been demonstrated in vitro and are thought 
to be responsible in part for variations in;
 a. Persistence 
 b. Pathogenicity 
 c. Carcinogenic risk
 d. Immunogenicity 
of the virus among different populations [42]. 
 The distribution of the variants is geographically 
and ethnically specific with the European type being 
global except for Sub-Saharan Africa where the African 
variants are more prevalent [43]. 
 The European variant has been isolated among 
cervical cancer patients in Tunisia and Morocco. 
Perhaps reflecting the proximity of the two nations to 
the European continent [33]. 
 Based on these observations, molecular sub-
typing of High-risk HPV types may provide crucial 
information with regard to geographical and ethnical 
disparity in HPV-related HNSCC.
 Several other logical explanations for low HPV 
presence in HNSCC in some areas have been proposed. 
These borrow heavily from other disease processes, but 
there is so far no evidence to support their role in HPV-
related HNSCC. 
 One such explanation proposes that a genital 
HPV infection acquired before HPV exposure through 
oral sex may evoke an immune response that decreases 
the risk of oral HPV and therefore HPV-related HNSCC 
[44]. 
 This may explain the high prevalence of HPV 
in cervical cancer but not in HNSCC in the same 
population. Geographical differences too, have been 
shown to influence distribution of certain diseases such 
as Sickle cell disease. 
 According to the malaria hypothesis, there 
exists malaria protection by haemoglobin S in certain 
geographical zones including Africa. This protection 
arises from both innate and acquired immunity to 
Plasmodium. falciparum [45]. 
 It is, therefore thought that perhaps, an 
equivalent immunological protection against HPV 
infection by some yet to be determined factor may exist 
in some geographical regions to explain the low HPV-
related HNC.
 Gene - environment interaction may also 
influence disease distribution. This has been 
demonstrated in oestrogen receptor - negative 
breast tumours which are prevalent among the poor 
communities [46]. 
 Based on these observations, it is postulated 
that different populations respond differently to given 
infections and this might be the case with HPV in head 
and neck cancer in some cases.
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 The most common HPV genotype associated 
with HNSCC is 16 followed by 18 [8, 34]. 
 This study did not have either of these. Several 
other studies from Africa either had none or only a few 
of HPV 16 and/or 18. In Morocco, a study on HPV in 
Nasopharyngeal Carcinoma detected HPV in 34% of 
specimens with HPV 31 in 20.8% of the specimens and 
the rest being types 59, 16, 18, 33, 35 and 45 [29]. 
 In Senegal, there were only 4 HPV positive 
cases out of 117 study subjects. The genotypes detected 
were 16, 35 and 45 but with no P16NK4a overexpression 
[15]. 
 Analysis of FFPE tissues from Nasopharyngeal 
Carcinoma patients in Ghana was positive for HPV in 
14(19.23%) cases 13 of which were type 18 and one type 
31 [47]. 
 This is in contrast to predominance of HPV 
type 16 in HNSCC specimens from the same country 
majority of which were from the larynx and oral cavity 
[22, 24]. 
 Curiously, a study that evaluated HPV from 
OSCC in Ghana yielded HPV in only 3.4% of the 
specimens [23].  
 Two studies from South Africa, though with 
very few positive cases, had HPV types 18, 16 and 11 
[10, 11].  
 A later study done in South Africa among male 
factory workers which sought to determine the oral and 
Oropharyngeal HPV strains and associated risk factors 
found a prevalence of 5.65%. Apparently the HPV types 
16 and 18 were found in two men with a history of oral 
sex [48]. 
 All characteristics considered, there was 
no patient or tumour factor from the current study 
predictive of HPV positivity.
 Both HPV and HIV have been classified by the 
International Agency for Research on Cancer (IARC) as 
Carcinogens. 
 The association between HIV and HNSCC 
is unclear with higher prevalence of HNSCC in HIV 
positive patients being attributed to immunosuppression, 
opportunistic infections and infection with high-risk 
HPV types. 
 In this study HPV positivity was 20% in the 
HIV-positive HNSCC patients only and 6.7% among the 
HIV-negative patients. 
 The difference is wide although the numbers 
involved were too few and may not permit any statistical 
inference to be made. Perhaps this begs for further 
studies to be done to unravel the relationship. 
 In the meantime, this is one group of patients in 
whom HPV determination can be considered especially 
where the other features that characterize HPV positive 
HNSCC are present.
Conclusion
 The prevalence of High-risk HPV among 
HNSCC patients at KNH is low (7.5%) with no HPV 
16 or 18. The positive patients do not have profiles that 
match those of HPV-positive HNSCC globally and there 
were no predictors of HPV presence. The prevalence of 
HPV is relatively higher in the HIV- positive HNSCC 
patients.
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